Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference
February 13 2009 - 9:55AM
PR Newswire (US)
BETHESDA, Md., Feb. 13 /PRNewswire-FirstCall/ -- Micromet, Inc.
(NASDAQ: MITI), today announced that its Chief Financial Officer,
Buck Phillips, will present at the ROTH 21st Annual Orange County
Growth Stock Conference at the Ritz-Carlton Laguna Niguel on
Wednesday, February 18, 2009. Forum: The ROTH 21st Annual Orange
County Growth Stock Conference Date: Wednesday, February 18, 2009
Time: 4:30 pm Pacific Time Place: The Ritz-Carlton Laguna Niguel
One Ritz Carlton Drive Dana Point, CA 92629 About Micromet, Inc.
Micromet, Inc. (http://www.micromet-inc.com/) is a
biopharmaceutical company with offices in Bethesda, MD and Munich,
Germany. The Company is focused on developing novel, proprietary
antibodies for the treatment of cancer, inflammation and autoimmune
diseases. The Company's novel antibody technology is based on its
proprietary BiTE(R) antibody platform, representing a new class of
antibodies that specifically activate T cells from the patient's
own immune system to eliminate cancer cells or other disease
related cells. Four of the Company's antibodies are currently in
clinical trials, with the remainder of its product pipeline in
preclinical development. The Company's lead program is a BiTE
antibody known as blinatumomab, or MT103. It is in a phase 2
clinical trial for the treatment of patients with acute
lymphoblastic leukemia and a phase 1 clinical trial for the
treatment of patients with non-Hodgkin's lymphoma. Micromet is
developing blinatumomab in collaboration with MedImmune, LLC, a
subsidiary of AstraZeneca plc. Micromet's second BiTE antibody in
clinical development is MT110, which targets the epithelial cell
adhesion molecule (EpCAM). The Company owns all rights to MT110,
which is currently in a phase 1 clinical trial for the treatment of
patients with solid tumors. The Company's third clinical stage
antibody is adecatumumab, also known as MT201, a traditional human
monoclonal antibody that targets EpCAM-expressing solid tumors.
Micromet is developing adecatumumab in collaboration with Merck
Serono in a phase 1b clinical trial evaluating adecatumumab in
combination with docetaxel for the treatment of patients with
metastatic breast cancer. Micromet licensed a fourth clinical stage
antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being
developed in a phase 1 clinical trial for the treatment of patients
with cancer. The Company's preclinical programs include MT203 being
developed in collaboration with Nycomed. MT203 is a traditional
human antibody neutralizing the activity of granulocyte/macrophage
colony stimulating factor (GM-CSF), which has potential
applications in the treatment of inflammatory and autoimmune
diseases, such as rheumatoid arthritis, psoriasis, or multiple
sclerosis. Micromet has granted an exclusive option to Bayer
Schering Pharma AG to license a BiTE antibody against an
undisclosed solid tumor target. Additional BiTE antibodies,
targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in
different stages of preclinical development. Forward-Looking
Statements This release contains certain forward-looking statements
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. These forward-looking statements include statements
regarding the efficacy, safety and intended utilization of our
product candidates, the development of our BiTE antibody
technology, the conduct, timing and results of future clinical
trials, expectations of the future expansion of our product
pipeline and collaborations, and our plans regarding future
presentations of clinical data. You are urged to consider
statements that include the words "ongoing," "may," "will,"
"believes," "potential," "expects," "plans," "anticipates,"
"intends," or the negative of those words or other similar words to
be uncertain and forward-looking. Factors that may cause actual
results to differ materially from any future results expressed or
implied by any forward-looking statements include the risk that
product candidates that appeared promising in early research,
preclinical studies or clinical trials do not demonstrate safety
and/or efficacy in subsequent clinical trials, the risk that
encouraging results from early research, preclinical studies or
clinical trials may not be confirmed upon further analysis of the
detailed results of such research, preclinical study or clinical
trial, the risk that additional information relating to the safety,
efficacy or tolerability of our product candidates may be
discovered upon further analysis of preclinical or clinical trial
data, the risk that we or our collaborators will not obtain
approval to market our product candidates, the risks associated
with reliance on outside financing to meet capital requirements,
and the risks associated with reliance on collaborators, including
MedImmune, Merck Serono, TRACON and Nycomed, for the funding or
conduct of further development and commercialization activities
relating to our product candidates. These factors and others are
more fully discussed in Micromet's Annual Report on Form 10-K for
the fiscal year ended December 31, 2007, filed with the SEC on
March 14, 2008, as well as other filings by the company with the
SEC. Any forward-looking statements are made pursuant to Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, and, as such,
speak only as of the date made. Micromet, Inc. undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise.
DATASOURCE: Micromet, Inc. CONTACT: US Media, Andrea tenBroek or
Chris Stamm, +1-781-684-0770, ; or European Media, Ludger Wess,
+49(40)8816-5964, ; or US Investors, Susan Noonan, +1-212-966-3650,
; or European Investors, Ines-Regina Buth, +49(30)2363-2768, Web
Site: http://www.micromet-inc.com/
Copyright